John Beveridge From: Herald Sun September 18, 2012
AUSTRALIAN biotechnology stocks tend to develop over time like a cellared wine and Bionomics is looking like it may become a tasty drop in a few years.
Yesterday's $9.5 million acquisition of San Diego's Eclipse Therapeutics not only adds some cancer stem cell treatments to the drug pipeline, it brings a crucial US presence that could prove pivotal in commercialising its other advanced drugs such as the solid tumour destroying BNC105.
By issuing shares to buy the company and adding the highly promising developments in cancer stem cell therapies, Bionomics should greatly broaden its investment appeal and anti-cancer focus without diluting shareholders too much. A speculative buy with the added fizz of a very promising anti-anxiety drug.
----------------------------
http://www.google.com.au/url?sa=t&rct=j&q=%22bionomics%22&source=web&cd=15&cad=rja&ved=0CEcQFjAEOAo&url=http%3A%2F%2Fwww.heraldsun.com.au%2Fbusiness%2Fin-the-black%2Fbhp-mothball-plan-makes-sense%2Fstory-e6frfinf-1226476095842&ei=XKVXUNuGOIHNmQXe1YGYBg&usg=AFQjCNHVPjyyRDGyzAHbsvk9S9OiCNTrRA
Add to My Watchlist
What is My Watchlist?